Parkinson's drug candidate to prove its worth in phase I – and lure big pharma to the table
Kariya Pharmaceutical has secured financing and a partner for early-stage testing of its lead asset against Parkinson’s – but the company dreams bigger after data is secure.
by albert rønning-andersson, translated by daniel pedersen & katrine gøthler
Biotech company Kariya Pharmaceuticals will soon achieve that which all early-stage biotech companies seek: to be sold or offered a partnership with a big pharmaceutical company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
